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Stroke thrombolysis in England, Wales and Northern
Ireland: how much do we do and how much do
we need?
A G Rudd, A Hoffman, R Grant, J T Campbell, D Lowe, On behalf of the
Intercollegiate Working Party for Stroke
ABSTRACT
Background Data are limited on the proportion of stroke
patients nationally appropriate for thrombolysis either
within the 3 h time window or the recently tested 4.5 h.
This information is important for the redesign of services.
Methods Data on case mix, eligibility for thrombolysis,
treatment and outcomes were extracted from the
National Sentinel Stroke 2008 Audit dataset. This
contains retrospective data on up to 60 consecutive
stroke admissions from each acute hospital in England,
Wales and Northern Ireland between 1 April and 30 June
2008.
Findings All relevant hospitals participated, submitting
data on 11 262 acute stroke patients. 2118 patients
arrived within 2 h and 2596 within 3 h of the onset of
symptoms and 587 people were already in hospital.
Therefore, 28% (3183) were potentially eligible for
thrombolysis based on a 3 h time criterion. Of these,
1914 were under 80 years and 2632 had infarction with
14% (1605) meeting all three National Institute of
Neurological Disorders and Stroke study criteria and so
being potentially eligible for thrombolysis. If the time
window is increased to 4.5 h then only another 2%
became eligible. If the age limit was removed for
treatment, the percentage potentially appropriate for
tissue plasminogen activator increased to 23% within 3 h
and 26% within 4.5 h. Overall, 1.4% (160) of patients
were thrombolysed.
Interpretation Thrombolysis rates are currently low in
the UK. 14% of patients in this sample were potentially
suitable for thrombolysis using the 3 h time window. This
would only increase marginally if thrombolysis was
extended to include those up to 4.5 h. The greatest
impact on increasing the proportion of patients suitable
for thrombolysis would be to increase the number of
patients presenting early and by demonstrating that the
treatment is safe and effective in patients over 80 years
of age.
INTRODUCTION
The evidence showing that thrombolysis is beneﬁ-
cial within 3 h1 and possibly 4.5 h2 of the onset of
ischaemic stroke symptoms is strong, with signiﬁ-
cant reduction in long term disability. The earlier
treatment is given, the greater the chance of a good
outcome. Thrombolysis for stroke is however
a treatment with a high risk of adverse effects,
particularly intracerebral haemorrhage, with an
8.7% incidence of symptomatic intracranial
bleeding (haemorrhage causing death or clinical
deterioration).1 Data from the Safe Implementation
of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST) register3 suggests a much lower rate
of bleeding (1.7%) but it is probable that there is
selection bias in this dataset and more weight
should be given to data from rigorous randomised
controlled trials. Evidence from centres reporting
the introduction of thrombolysis into routine clin-
ical care has highlighted the importance of skilled
clinical management in minimising the risk of
complications. Cleveland, Ohio, USA, reported
a 15% symptomatic haemorrhage rate in the ﬁrst
year of practice4 which resulted from widespread
failure to adhere to inclusion and exclusion criteria
for treatment. The UK has been slow to adopt
thrombolysis compared with some other
countries,5e7 with less than 0.2% of patients
reported to have received the treatment in the 2006
National Sentinel Audit of Stroke.8 A few centres
have developed effective acute care and are throm-
bolysing a signiﬁcant proportion of their patients.9
The Department of Health National Stroke
Strategy in England10 has been published which
identiﬁes, among many other aspects of stroke care,
the need to improve public awareness of stroke and
the need to develop services that deliver high
quality acute care, including thrombolysis, when
appropriate. The National Institute for Health and
Clinical Excellence (NICE) guidance was published
on acute stroke care in 2008 in England,11 following
on from a Technology Appraisal in 2007,12 and it
recommends the use of thrombolysis.
It is important that services, currently in the
process of major restructuring to deliver effective
acute stroke care, know the size of the problem
they will have to deal with. This study is one of
the ﬁrst to report national level data covering all
hospitals and describing potential requirements
for stroke thrombolysis. The aims of this study
were:
< To use national audit data to establish the
proportion of patients receiving thrombolysis
and compare this to the proportion that could
beneﬁt.
< To assess the proportion of patients that might
be eligible for thrombolysis if treatment was
extended from 3 h to 4.5 h and if the treatment
was routinely given to patients over 80 years.
< To assess the effect of the time of day of hospital
admittance on the availability of thrombolysis.
< To establish whether patients receiving throm-
bolysis are admitted to an adequately equipped
acute stroke unit.
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METHODS
The National Sentinel Audit of Stroke has been conducted
biannually since 1998 with participation currently from all
hospitals treating acute stroke patients in England, Wales and
Northern Ireland. The audit tool uses standards based on best
available evidence,13 and was developed by the Intercollegiate
Stroke Working party that includes a wide range of experts from
specialities involved in delivering stroke care as well as user
representatives. All hospitals within England, Wales, Northern
Ireland and the Channel Islands were invited to take part in the
sixth round of the National Sentinel Audit of Stroke. The
minimum requirements were that they had inpatient services
for stroke patients and had admitted at least 20 patients with
a primary diagnosis of stroke (ICD10 I61, I63 and I64) between 1
April and 30 June 2008. Details of the audit questionnaire are
available at http://www.rcplondon.ac.uk/stroke. The clinical
proforma was completed on up to 60 consecutive patients
(median 59 per hospital), 1 April and 30 June 2008, to assess
compliance with evidence based standards, to deﬁne case mix
and outcome. Using a web based tool with inbuilt validation,
very high levels of data completeness and internal consistency
were achieved. An inter-rater reliability study was conducted on
the ﬁrst ﬁve patients to estimate the agreement in data as
collected by a second auditor with access to the same informa-
tion and this demonstrated good to excellent levels of agreement
(median k¼0.77, IQR 0.67e0.86, n¼77 categorical questions).
The data collected covered the whole inpatient stroke
pathway but did not cover all the inclusion and exclusion
criteria as deﬁned by the National Institute of Neurological
Disorders and Stroke (NINDS) study14 (ie, uncontrolled hyper-
tension, profound premorbid dependency or current use of
anticoagulants). However, data from the 2006 audit which did
record premorbid disability and use of anticoagulation prior to
admission suggest the number of patients excluded for reasons
other than time since stroke onset (more than 3 h and more than
4.5 h), age over 80 years and haemorrhage on brain imaging is
likely to be relatively small. We did not collect the data in the
2008 audit for the number of patients admitted on anticoagu-
lants or on Barthel prior to admission.
Data were cleaned and analysed at the Royal College of
Physicians’ Clinical Effectiveness and Evaluation Unit, using
SPSS V.15 software. Times of admission and thrombolysis were
collected to the minute but many participants rounded times to
wider intervals, including the nearest hour in some cases, so we
present time to thrombolysis to the nearest hour. This will have
only a small impact on overall eligibility for reasons discussed
below under ‘Relaxing the NINDS criteria’. All data were
submitted by individual hospitals without any patient identi-
ﬁers. Where admission times were not known, we assumed that
these patients would not have been eligible for tissue plasmin-
ogen activator (tPA). Ethics approval was not required for this
audit and individual patient consent was not obtained.
RESULTS
All eligible hospitals (216) treating acute stroke patients partic-
ipated in the audit and they submitted data on 11 369 patients.
Of these, 107 were excluded for this paper as they received
rehabilitation care only. This left 215 hospitals (England n¼183,
Wales n¼18, Northern Ireland n¼11 and Islands n¼3) and 11
262 patients. Some 47% (5306) of patients were male, mean age
72 years, with 53% (5956) female, mean age 79 years. Motor
deﬁcits were recorded in 77% (8668), dysphasia in 39% (4425)
and dysarthria in 39% (4384). Of the 96% (10849) receiving
a brain scan, 87% (9431) had infarction on the scan and 13%
(1418) haemorrhage. At some point in the ﬁrst week after the
stroke, 13% (1476/11262) of patients were recorded as being
unconscious. This was higher for haemorrhagic strokes (30%,
423/1418) than infarctions (8%, 797/9431). Seventy-eight per
cent (8495/10859) were independent in everyday activities
before the stroke.
Eligibility for and receipt of thrombolysis
The date of stroke was known for 77% (8670) and was esti-
mated by hospitals in 23% (2587); data were missing for ﬁve
cases. The time of stroke during the day was known for 58%
(5031/8670) while 30% (1075/3639) of those with unknown
times occurred during sleep. The time of stroke and the time of
admission to hospital were both known for 4980, with 262 of
these being inpatients at the time of onset. Stroke and admission
times were subject to a certain degree of rounding, particularly
to the nearest half and full hours, and to accommodate this the
time elapsing between stroke and admission was rounded to the
nearest hour and was computable for 4600 of the 4718 patients
admitted after onset of symptoms. Of these, 46% (2118) arrived
at the hospital within 2 h of onset, 56% (2596) within 3 h, 64%
(2944) within 4 h and 70% (3223) within 5 h.
There were 587 inpatients at the time of stroke and so overall
28% (2596+587¼3183/11 262) were potentially eligible for
thrombolysis based on the 3 h time criterion assuming that the
majority of patients in a hospital bed should expect to have
acute stroke recognised within 3 h of the onset of symptoms
although some would not be eligible for reasons such as recent
surgery or comorbidities. Of these, 1914 (17%) were younger
than 80 years and 2632 (23%) had infarction. In all, 14% (1605/
11262) met all three criteria and were therefore potentially
eligible. Only 10% (160/1605) of the eligible patients were
thrombolysed and half (80) of these were from just 14 hospitals.
Almost all hospitals (209) had at least one eligible patient and 65
of these gave thrombolysis to some eligible patients. Of the 9657
patients who were not strictly eligible under the NINDS criteria,
44 (0.5%) received thrombolysis and 24 of these were aged over
80 years, 10 were admitted within 4.5 h and none was an
inpatient at the time of stroke.
Hospital variation in eligibility for and receipt of thrombolysis
The percentage of patients available for thrombolysis within 3 h
of symptoms varied between hospitals (median 28%, IQR
21e35%). The percentage of patients meeting all three NINDS
criteria varied (median 13%, IQR 9e18%). Only 31% (65/209) of
hospitals with eligible patients used thrombolysis, and these 65
hospitals treated a median of 20% (IQR 14e33%) of eligible
patients. Hospitals with larger numbers of eligible patients were
more likely to treat (Spearman r¼0.28, p<0.001) (table 1).
Relaxing the NINDS criteria
Overall, 32% (3558) were admitted within a 4.5 h window and
35% (3960) within 6 h, including inpatients at onset. Removing
the age restriction increased potential eligibility for patients
Table 1 Receipt of thrombolysis according to the number of eligible
patients
41 hospitals
with >10
eligible
patients
60 hospitals
with 8e10
eligible
patients
63 hospitals
with 5e7
eligible
patients
45 hospitals
with 1e4
eligible
patients
% (n) patients
treated
16% (90/577) 7% (39/530) 6% (23/366) 6% (8/132)
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with infarction from 14% to 23% (2632) for the 3 h window, to
26% (2951) within 4.5 h and to 29% (3294) within 6 h. Main-
taining the age restriction but extending the time window to
4.5 h increased eligibility from 14% to 16% (1811).
Time of admission to hospital
Time of admission was known for 10 538 (94%) stroke patients
who were admitted to hospital. Two-thirds of these (67% (7070/
10538)) were admitted between 08:00 and 18:00 h, of whom 13%
(903) were eligible under NINDS, while 33% (3468/10538) were
admitted between 19:00 and 07:00 h of whom 13% (446) were
eligible. Signiﬁcantly more eligible patients received thrombolysis
between 08:00 and 18:00 h than outside these hours (14% (126/
903) vs 5% (24/446); p<0.001). Of 587 inpatients at the time of
stroke, 44% (256) were eligible, of whom 3.9% (10) were treated.
Figure 1 shows the variation in time of day for the 10 538
admitted patients, and within this the variation in numbers
eligible for and treated by thrombolysis can be seen.
Gender
Whereas 18% (937/5306) of men were eligible using NINDS
criteria, only 11% (668/5956) of women were eligible. Female
patients were however older thanmale patients and if theNINDS
age restriction is relaxed, then 24% (1277/5306) of men would be
eligible and 23% (1355/5956) of women. Rates overall for men
and women entering hospital within 3 h of onset, including
existing inpatients, were similar at 29% (1525/5306) and 28%
(1658/5956), respectively, and rates for infarction on brain scan-
ning were also very similar at 87% (4914/5667) for women and
87% (4517/5182) for men. A lower proportion of eligible women
(9%, 61/668) received thrombolysis than eligible men (11%,
99/937) but this was not statistically signiﬁcant (p¼0.35).
Case mix and admission characteristics
Variables applying at onset or at admission or soon after are
summarised in table 2. Eligibility rates did not display much
variation between patient subgroups apart from existing inpa-
tients (44%). Eligibility variation overall is explainable by the
associations between these variables and the factors (admission
<3 h, brain scan infarction, age 80 years or under) determining
the NINDS criteria. The overall treatment rate for eligible
patients was 10% and there was notable variation (table 1) in
relation to age (under 65s 13% vs 65e80s 9%), in being capable
of independent living before the stroke (yes 11% vs no 4%), prior
comorbidities (none 18% vs one or more 8%), use of lipid
lowering treatment prior to stroke (yes 8%, no 12%), having an
ambulance patient record on ﬁle and Face, Arm, Speech Test
(FAST) available (yes 21% vs no 7%), being admitted during
working hours (08:00e18:00 h 14% vs 19:00e07:00 5% vs
existing inpatient 4%) and having dysphasia, dysarthria and
motor deﬁcits during the ﬁrst 24 h (none 1% vs one 4% vs
two/three 14%). The worst level of consciousness at the time of
maximum severity in the ﬁrst week after stroke did not predict
thrombolysis use nor did current smoking or alcohol excess.
Acute stroke units and ambulance records
Within 4 h of admission to hospital, 69% (111/160) of eligible
and thrombolysed patients were admitted to an acute or
combined stroke unit. This compares with 19% (275/1445) of
those eligible but not thrombolysed. Five characteristics were
used in the audit to identify quality of care in acute or combined
stroke units. These were continuous physiological monitoring
(ECG, oximetry, blood pressure), access to scanning within 3 h
of admission, direct admission from the accident and emergency
department, specialist ward rounds at least ﬁve times a week
and presence of acute stroke protocols/guidelines. Some 111 of
191 sites with acute or combined stroke units possessed only
four or fewer of these characteristics and 17 of these 111 carried
out thrombolysis on eligible patients in this audit. These 17 sites
had 145 eligible patients and thrombolysed 21% (31) of them.
Therefore, 19% (ie, 31/160) of all eligible and thrombolysed
patients were thrombolysed in centres without fully equipped
acute specialist stroke beds.
Outcomes
Inpatient mortality was 12% (19/160) for eligible treated patients
and 14% (208/1445) for those not treated (14%, 208/1445).
Thirty day mortality was 12% (19/156) versus 12% (169/1386),
respectively, excluding unknown outcomes. New institutionali-
sation rates for eligible and discharged patients were 4% (6/137)
and 7% (81/1196), respectively. Length of stay was known for
1595 eligible patients and median (IQR) stays for treated and
untreated patients were 9 (4e24) days and 12 (5e31) days,
respectively. The numbers are too small to meaningfully stratify
by further organisational or clinical features.
DISCUSSION
A number of centres have reported their local stroke thrombol-
ysis rates, ranging from 1.6% to 18%.15e18 Several authors have
attempted to model the number of potential patients suitable
for thrombolysis from hospital and population based registers,
again with large differences between studies, ranging from
0.4%19 of patients beneﬁting from treatment to 8% in Cincin-
nati20 and 24%21 in The Netherlands, suitable to be treated. This
study however provides one of the ﬁrst estimates at a national
level of the provision of and need for thrombolysis services. It
shows that about 14% of patients admitted to hospital with
acute stroke are likely to be eligible for thrombolysis, and that
only 10% of these patients actually receive it (1.4% of the total
stroke population). Provision of a daytime service alone without
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Figure 1 Time of day patients admitted to hospital for whole cohort
divided by eligibility for, and provision of, thrombolysis (n¼10 538
admitted).
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access to night-time acute stroke care will result in a signiﬁcant
number of patients being denied best quality care. Twenty-four
hour services are therefore essential. These data show that
a major step change in stroke care is feasible by improved
delivery of care. Provision of high quality acute stroke services,
accessible to the whole population rather than the current
Table 2 Case mix and admission characteristics in relation to eligibility for, and if eligible the provision of, thrombolysis (n¼11 262 unless stated
otherwise)
Per cent
Eligible
patients Per cent
Treated
patients
p Value
for treatment*
Age (if not over 80 years) <55 23 181/804 14 26/181 0.004
55e64 24 312/1303 13 39/312
65e74 25 569/2299 8 47/569
75-80 25 543/2205 9 48/543
Sex Male 18 937/5306 11 99/937 0.35
Female 11 668/5956 9 61/668
Worst level of consciousness at time of
maximum severity within first week after
stroke (known for 11 261)
Unconscious (responds to pain only/no
response)
10 143/1476 10 14/143 0.82
Semi-conscious (not fully rousable) 12 104/859 10 10/104
Drowsy 15 287/1959 11 33/287
Fully conscious 15 1071/6967 10 103/1071
Patient independent in everyday activities
before stroke (eg, Barthel 19e20, Rankin
<3)
Yes 16 1388/8495 11 153/1388 0.002
Yes vs NoNo 8 182/2364 4 7/182
Not known 9 35/403 0 0/35
Time of admission (known for 10 538 who
were admitted after stroke)
Working hours (08:00e18:00) 13 903/7070 14 126/903 <0.001
WH vs OOHOut of hours 13 446/3468 5 24/446
Already an inpatient 44 256/587 4 10/256
Ambulance clinicians’ patient record on
file and FAST available
Yes 18 433/2474 21 90/433 <0.001Yes vs no
No 12 717/6212 7 51/717
Not applicable 18 455/2576 4 19/455
Use of any lipid lowering treatment before
admission
Yes 17 728/4255 8 56/728 0.006
No 13 877/7007 12 104/877
No of known comorbidities before
admission (range 0e7 as listed below)
0 14 298/2133 18 54/298 <0.001
1 or 2 13 826/6155 9 74/826
3 or more 16 481/2974 7 32/481
Atrial fibrillation Yes 13 317/2462 7 23/317 0.08
No 15 1288/8800 11 137/1288
Previous stroke/TIA Yes 13 439/3260 6 27/439 0.001
No 15 1166/8002 11 133/1166
Diabetes Yes 16 314/1963 6 20/314 0.016
No 14 1291/9299 11 140/1291
Hyperlipidaemia (total cholesterol >5
or LDL >3.0 mmol/l
Yes 17 484/2806 9 44/484 0.47
No 13 1121/8456 10 116/1121
Hypertension (systolic >140 or
diastolic >85)
Yes 14 893/6239 8 75/893 0.023
No 14 712/5023 12 85/712
Myocardial infarction or angina Yes 17 360/2166 6 20/360 0.001
No 14 1245/9096 11 140/1245
Valvular heart disease (aortic or mitral
valves)
Yes 17 67/395 6 4/67 0.40
No 14 1538/10867 10 156/1538
No of dysphasia, dysarthria, motor
deficits during the first 24 h
0 10 142/1477 1 1/142 <0.001
1 13 503/3938 4 22/503
2 17 672/4002 13 89/672
3 16 288/1845 17 48/288
Dysphasia Yes 15 676/4425 14 97/676 <0.001
Yes vs noNo 15 829/5693 7 61/829
Not known 9 100/1144 2 2/100
Dysarthria Yes 16 723/4384 13 96/723 0.001
Yes vs noNo 14 750/5373 8 60/750
Not known 9 132/1505 3 4/132
Motor deficits Yes 15 1312/8668 12 151/1312 <0.001
Yes vs noNo 12 249/2071 4 9/249
Not known 8 44/523 e 0/44
Current smoker Yes 20 369/1850 10 37/369 0.99
No 13 1236/9412 10 123/1236
Alcohol excess (no of units per week >21
for females, >28 males
Yes 18 120/683 10 12/120 0.99
No 14 1485/10579 10 148/1485
*Fisher’s exact test was used, except for where the ManneWhitney test was used with age in years and where c2 test was used for worst level of consciousness, No of comorbidiy groups
and No of known symptoms limiting physical function.
FAST, Face, Arm, Speech Test; LDL, low density lipoprotein; TIA, transient ischaemic attack.
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patchy delivery of care, should be able to increase the number of
patients thrombolysed 10-fold. The most important actions,
within current European licensing, to increase the proportion of
patients eligible for treatment, will be to reduce the delay
between onset of symptoms and arrival in hospital and to ensure
that all hospitals treating acute stroke patients should have the
skills and resources to offer thrombolysis at all times. This will
require both increased public awareness and better professional
management in the prehospital phase. It has been shown that
where the FAST22 is being used patients are more likely to be
thrombolysed but this may simply reﬂect services organising
themselves to deliver care effectively. An Australian randomised
controlled trial has shown that a prehospital protocol increases
access to treatment23 and this has also been demonstrated in the
USA.24 Improving public awareness of the symptoms of stroke
and how to respond when they happen is being addressed in
England with a major advertising campaign funded by the
Department of Health and ongoing awareness raising by the
Stroke Association, although the efﬁcacy of such campaigns
remains unproven. A recent study reported a signiﬁcant increase
in the proportion of patients thrombolysed admitted to
academic medical centres in the USA between 2001 and 2004
from 14% of those admitted within 2 h of symptom onset to
37.5%, but with no signiﬁcant increase in the proportion
arriving within 2 h (37e38%).25
Offering tPA up to 4.5 h is only going to marginally increase
the rates of thrombolysis and because of the high number
needed to treat between 3 and 4.5 h2 this change in practice will
have a small impact on outcomes at a population level. The
message that treatment is still available up to 4.5 h may actually
make outcomes worse if there is a mistaken belief that the
patients and professionals can afford to take their time and
therefore not treat each case as an emergency. Approximately
40% of patients who are in hospital within 3 h of stroke are
excluded from thrombolysis when delivered according to the
European license because they are over the age of 80 years. The
trial currently being funded by the MRC (IST 3) evaluating
among other things whether the drug can be given safely and
effectively to older patients is therefore of major importance and
if shown would have the greatest impact on the proportion of
patients eligible for thrombolysis. If the ongoing trials of
treating patients with mismatch on diffusion/perfusion scan-
ning show positive results, then again a signiﬁcant increase in
the number of patients eligible for treatment would be expected
as some of the patients with ‘wake up’ strokes and those with
unknown time of onset could be treated.
These data show marked differences between centres in the
proportion of patients meeting the NINDS eligibility criteria but
this is consistent with random variation between hospitals with
relatively small sample sizes. That these data do not show
signiﬁcant differences in outcome between those treated and not
treated with thrombolysis is likely to reﬂect the very small
numbers of patients that were treated. These are observational
data, not a randomised controlled trial, and differences may also
reﬂect any local level selection biases for thrombolysis in eligible
patients due to their clinical condition . The Cochrane review1
shows that treatment is worthwhile and the SITS-MOSTaudit3
suggests that the treatment can be delivered safely in routine
clinical practice although it must be acknowledged that this
database may not represent a complete record of all thrombol-
ysis treatments given and may therefore have some bias. What
we have shown that is very concerning is that some centres
appear to be delivering thrombolysis without the highest quality
stroke service in place to support the treatment. Thrombolysis is
only one relatively small component of acute stroke care and
should only be provided when a high quality environment is
established. NICE guidance11 12 states that alteplase should only
be administered within a well organised stroke service with staff
trained in delivering thrombolysis and in monitoring for any
associated complications, care up to level 1 and level 2 nursing
staff trained in acute stroke and thrombolysis immediate access
to imaging. Additionally, many centres providing thrombolysis
are only treating very small numbers of patients. Data from the
German Stroke Registers Study Group26 have shown that
outcomes are better from units performing at least 15 proce-
dures per year. This would suggest that reorganisation of care
should concentrate acute stroke care in a smaller number of
larger specialist centres. The Stroke Organisational audit in
200927 showed that, of 210 sites providing acute care, 138 (66%)
claimed to have thrombolysis available on site, but only 47 (22%
of all acute sites) had administered the treatment to 15 or more
patients in the previous year. These numbers are something of
an improvement on the organisational audit in 200828 which
showed that, of 213 sites providing acute care, 91 (43%) claimed
to have thrombolysis available on site but only 22 (10% of all
acute sites) had administered treatment to 15 or more patients
in the previous year. One-third of patients (446/1605¼28%)
eligible for thrombolysis were admitted outside normal working
hours (08:00 through 18:00 h) and these data show that 24 h,
7 days a week acute stroke care is essential.
The strengths of this study are that it involves all acute stroke
providers in England, Wales and Northern Ireland and uses
a well established and accepted methodology29 that has been
used by local hospitals, strategic health authorities and
government to develop services. The potential weaknesses are
that the number of patients included from each centre is rela-
tively small and the total number of patients treated with
alteplase within the sample is very small. Data are self-reported
and may therefore be open to bias, both through patient
selection and inaccuracy in reporting. We do not believe that
this is a major factor, particularly for the data items used in this
analysis, given the good inter-rater reliability. Data were not
collected that enabled complete certainty about the proportion
of patients that were eligible for thrombolysis but the numbers
in clinical practice that are excluded because of these factors
such as hypertension, recent bleeding and use of anticoagulants
are relatively small. In the 2006 audit, 7% of patients were
admitted on warfarin, 78% were independent prior to admission
(Barthel 19 or 20 or a Rankin of <3) with only 7% (from the
2001e2002 audit) being so severely impaired prior to the stroke
as to preclude the use of thrombolysis, with a Barthel of less
than 10. There is also some uncertainty about the time from
onset to admission due to rounding of times to the nearest hour,
and there are some patients for whom the admission times were
not known. Thrombolysis is an important component of stroke
care that is currently applicable to about 14% of the stroke
population. In England, Wales and Northern Ireland, only 10%
of eligible patients are currently receiving the treatment.
Extending the thrombolysis time window from 3 to 4.5 h will
have a minimal effect on the number of patients treated. The
major factors that might increase the number will be if it can be
shown that the drug can be given safely to patients over the age
of 80 years and public awareness increases so that a greater
proportion of patients arrive within the hospital in time to be
treated.
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